FDA Approves Short-Acting Insulin Admelog to Treat Diabetes

December 11, 2017. The US Food and Drug Administration (FDA) announced the approval of Admelog (insulin lispro injection), a short-acting insulin indicated to improve blood glucose control in adult and pediatric patients ≥3 years of age with type 1 diabetes and adults with type 2 diabetes. Admelog is the first short-acting insulin approved as a “follow-on” product via the FDA’s 505(b)(2) pathway. It is recommended that healthcare providers monitor potassium levels in patients taking Admelog who are at risk for hypokalemia. Read the full FDA announcement here.